CAS 2271119-26-5

CSF1R-IN-2

CAS : 2271119-26-5

CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).

Formule : C₂₀H₂₀FN₇O₂

Degré de pureté : 99.29%

Couleur et forme : Solid

Masse moléculaire : 409.42

Ref: TM-T13194

CSF1R-IN-2

CAS : 2271119-26-5

CSF1R-IN-2

Formule : C₂₀H₂₀FN₇O₂

Degré de pureté : ≥98%

Masse moléculaire : 409.42

Ref: 54-BUP08914

Elzovantinib

CAS : 2271119-26-5

(S)-12-Amino-2-ethyl-45-fluoro-6-methyl-9-oxo-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenacyclononaphane-46-carbonitrile

Formule : C₂₀H₂₀FN₇O₂

Degré de pureté : 99%

Masse moléculaire : 409.42

Ref: IN-DG01117669

CSF1R-IN-2

CAS : 2271119-26-5

CSF1R-IN-2 is a potent inhibitor of human tumor kinases that has been shown to have anticancer properties. It is a kinase inhibitor that targets the CSF1R protein, which is involved in cancer cell growth and survival. CSF1R-IN-2 has been found to induce apoptosis in cancer cells and inhibit tumor growth in animal models. This medicinal analog has been developed as a potential treatment for various types of cancer, including lung, breast, and pancreatic cancer. It is also being studied as a potential therapeutic agent for other diseases such as Alzheimer's disease and multiple sclerosis. CSF1R-IN-2 is excreted through urine and has shown promising results in Chinese clinical trials as an effective anticancer drug.

Formule : C₂₀H₂₀FN₇O₂

Degré de pureté : Min. 95%

Masse moléculaire : 409.4 g/mol

Ref: 3D-WQD11926